Current opportunities for vaccine prophylaxis of common infections in immunosuppressed adult patients
https://doi.org/10.51523/2708-6011.2021-18-2-1
Abstract
One of the slogans of modern clinical vaccinology is — “You have taken enough care of your children’s health, and now it is time to take care of yourselves and your parents — it is high time to think seriously about vaccinating adults!” It is indeed true that for a long time vaccinology has been confined to the paediatric service only, while general practitioners and specialists of the therapeutic branches of medicine have dealt with vaccination very rarely, and only in relation to seasonal influenza. This is often due to the fact that clinicians often have insufficient or inaccurate information regarding the need for and the effectiveness of vaccination in adult patients, including those with immunosuppression or comorbidity. In some cases, the infrastructure needed to develop a tailored vaccination schedule for adult patient groups at increased risk of developing infectious complications is lacking. This article presents current data with regard to vaccination of immunosuppressed adult patients.
About the Author
I. O. Stoma
Gomel State Medical University
Belarus
Belarus
Igor O. Stoma, DMedSc, Associate Professor, Rector
Gomel
References
1. Kano H, Mizuta K, Sakakihara Y, Kato H, Miki Y, Shibuya N, et al. Efficacy and safety of immunization for pre- and post- liver transplant children. Transplantation. 2002 Aug 27;74(4):543–550. https://doi.org/10.1097/00007890-200208270-00020
2. National Center for Immunization and Respiratory Diseases. General recommendations on immunization — recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011 Jan 28;60(2):1–64.
3. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014 Feb;58(3):e44-100. https://doi.org/10.1093/cid/cit684
4. Goyal S, Pai SK, Kelkar R, Advani SH. Hepatitis B vaccination in acute lymphoblastic leukemia. Leuk Res. 1998 Feb;22(2):193–195. https://doi.org/10.1016/s0145-2126(97)00155-0
5. Zengin E, Sarper N. Humoral immunity to diphtheria, tetanus, measles, and hemophilus influenzae type b in children with acute lymphoblastic leukemia and response to re-vaccination. Pediatr Blood Cancer. 2009;53(6):967–972. https://doi.org/10.1002/pbc.22135
6. Yu JW, Borkowski A, Danzig L, Reiter S, Kavan P, Mazer BD. Immune response to conjugated meningococcal C vaccine in pediatric oncology patients. Pediatr Blood Cancer. 2007 Dec;49(7):918–923. https://doi.org/10.1002/pbc.21174
7. Ercan TE, Soycan LY, Apak H, Celkan T, Ozkan A, Akdenizli E, et al. Antibody titers and immune response to diphtheria-tetanus-pertussis and measles-mumps-rubella vaccination in children treated for acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2005 May;27(5):273–277. https://doi.org/10.1097/01.mph.0000163214.37147.5a
8. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020;323(18):1775–1776. https://doi.org/10.1001/jama.2020.4683
9. Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020 Jul;31(7):894–901. https://doi.org/10.1016/j.annonc.2020.03.296
10. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020 Mar;21(3):335–337. https://doi.org/10.1016/S1470-2045(20)30096-6
11. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010 Aug 6;59(RR-8):1–62
12. Ljungman P, Andersson J, Aschan J, Barkholt L, Ehrnst A, Johansson M, Weilan O. Influenza A in immunocompromised patients. Clin Infect Dis 1993 август;17(2):244–247. https://doi.org/10.1093/clinids/17.2.244
13. de Lavallade H, Garland P, Sekine T, Hoschler K, Marin D, Stringaris K, et al. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica. 2011;96(2):307–314. https://doi.org/10.3324/haematol.2010.032664
14. Parkman R, Weinberg KI. Immunological reconstitution following bone marrow transplantation. Immunol Rev. 1997 Jun;157(1):73–78. https://doi.org/10.1111/j.1600-065x.1997.tb00975.x
15. Yri OE, Torfoss D, Hungnes O, Tierens A, Waalen K, Nordøy T, et al. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood. 2011 Dec 22;118(26):6769–6771. https://doi.org/10.1182/blood-2011-08-372649
16. Elting LS, Whimbey E, Lo W, Couch R, Andreeff M, Bodey GP. Epidemiology of influenza A virus infection in patients with acute or chronic leukemia. Support Care Cancer. 1995 May;3(3):198–202. https://doi.org/10.1007/BF00368891
17. Earle CC. Influenza vaccination in elderly patients with advanced colorectal cancer. J Clin Oncol. 2003 Mar 15;21(6):1161–1166. https://doi.org/10.1200/JCO.2003.06.008
18. Anderson H, Petrie K, Berrisford C, Charlett A, Thatcher N, Zambon M. Seroconversion after influenza vaccination in patients with lung cancer. Br J Cancer. 1999 Apr;80(1-2):219–220. https://doi.org/10.1038/sj.bjc.6690342
19. Meerveld-Eggink A, de Weerdt O, van der Velden AMT, Los M, van der Velden AWG, Stouthard JML, et al. Response to influenza virus vaccination during chemotherapy in patients with breast cancer. Ann Oncol. 2011 Sep;22(9):2031–2035. https://doi.org/10.1093/annonc/mdq728
20. Nordøy T, Aaberge IS, Husebekk, A, Samdal HH, Steinert S, Melby H, et al. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumonia. Med. Oncol. 2002;19(2):71–78. https://doi.org/10.1385/MO:19:2:71
21. Robertson JD, Nagesh K, Jowitt SN, Dougal M, Anderson H, Mutton K, et al. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer. 2000 Apr;82(7):1261–1265. https://doi.org/10.1054/bjoc.1999.1088
22. Centers for Disease Control and Prevention (CDC). Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. MMWR Morb Mortal Wkly Rep. 2012 Jun 1;61(21):394–395.
23. Hammarström V, Pauksen K, Björkstrand B, Simonsson B, Oberg G, Ljungman P. Tetanus immunity in autologous bone marrow and blood stem cell transplant recipients. Bone Marrow Transplant. 1998 Jul;22(1):67–71. https://doi.org/10.1038/sj.bmt.1701289
24. Patel SR, Ortín M, Cohen BJ, Borrow R, Irving D, Sheldon J, Heath PT. Revaccination of children after completion of standard chemotherapy for acute leukemia. Clin Infect Dis. 2007 Mar 1;44(5):635–642. https://doi.org/10.1086/511636
25. Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, Behrens J, Smith A, Child JA, Drayson MT. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005 Dec 20;23(36):9219– 9226. https://doi.org/10.1200/JCO.2005.03.2086
26. Blimark C, Holmberg E, Mellqvist UH, Landgren O, Björkholm M, Hultcrantz M, Kjellander C, Turesson I, Kristinsson SY. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015 Jan;100(1):107–113. https://doi.org/10.3324/haematol.2014.107714
27. Stoma I, Karpov I, Iskrov I, Lendina I, Uss A. Clinical efficacy of pneumococcal vaccination in multiple myeloma patients on novel agents: Results of a prospective clinical study. Vaccine. 2020 Jun 19;38(30):4713–4716. https://doi.org/10.1016/j.vaccine.2020.05.024
Review
For citations:
Stoma I.O. Current opportunities for vaccine prophylaxis of common infections in immunosuppressed adult patients. Health and Ecology Issues. 2021;18(2):5-11. (In Russ.) https://doi.org/10.51523/2708-6011.2021-18-2-1
Views: 466
Email this article 